z-logo
Premium
Smoking reduction treatment with 4‐mg nicotine gum: A double‐blind, randomized, placebo‐controlled study
Author(s) -
Batra Anil,
Klingler Karl,
Landfeldt Björn,
Friederich Hubertus M.,
Westin Åke,
Danielsson Tobias
Publication year - 2005
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/j.clpt.2005.08.019
Subject(s) - nicotine gum , nicotine , placebo , abstinence , medicine , smoking cessation , randomized controlled trial , harm reduction , concomitant , anesthesia , psychiatry , public health , alternative medicine , nursing , pathology
Background Smoking reduction may provide a harm‐reduction alternative treatment for smokers who are not ready to quit smoking. This study evaluated the efficacy of nicotine gum in helping smokers reduce or quit smoking. Methods This randomized, double‐blind, placebo‐controlled trial involved 364 smokers who were not ready to quit but were willing to reduce their smoking intensity. Participants received either 4‐mg nicotine gum (n = 184) or placebo gum (n = 180) as desired for up to 12 months. The primary outcome was sustained smoking reduction, which was defined as a decrease in daily cigarette consumption of at least 50% compared with baseline. Secondary measures included point‐prevalence abstinence, intention to quit, and cardiovascular risk markers. Results At 4 months, the sustained smoking reduction rate in the nicotine gum group was twice that of the placebo group (15.8% versus 6.7%, P = .008). Point‐prevalence abstinence was 6.6% for the nicotine gum group and 2.2% for the placebo group ( P = .07). At 13 months, there was a significant difference in the smoking reduction rate for the nicotine (8.2%) and placebo (2.8%) groups ( P = .036). At month 13, the abstinence rates were 12% and 4.5% for the nicotine and placebo groups, respectively ( P = .012). Concomitant use of nicotine gum and cigarette smoking was well tolerated. Carbon monoxide levels decreased significantly ( P = .01). Conclusion Nicotine gum may be an efficacious harm‐reduction alternative for smokers who are not ready to quit and may promote smoking cessation, the ultimate goal in the treatment of tobacco dependence. Clinical Pharmacology & Therapeutics (2005) 78 , 689–696; doi: 10.1016/j.clpt.2005.08.019

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here